Overview

Pharmaco-immunological Study of Interferon-alpha and Metronomic Cyclophosphamide Association in Neuroendocrine Tumors

Status:
Completed
Trial end date:
2021-06-29
Target enrollment:
Participant gender:
Summary
This study will evaluate the potential immunomodulatory synergy of the association of metronomic cyclophosphamide (CMC) and interferon-alpha (IFN-alpha).
Phase:
Phase 2
Details
Lead Sponsor:
Centre Hospitalier Universitaire de Besancon
Treatments:
Cyclophosphamide
Interferon-alpha
Interferons